Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has entered into a clinical trial collaboration with biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) to evaluate ivonescimab in combination with GSK's investigational B7-H3 antibody drug conjugate, risvutatug rezetecan, across multiple solid tumour settings, including small cell lung cancer.

Ivonescimab is a novel, investigational PD-1 / VEGF bispecific antibody.

The collaboration with GSK aims to assess the safety profile and potential anti-tumour activity of the combination therapy.

Under the agreement, Summit will supply ivonescimab, while GSK will oversee day-to-day clinical trial operations. Each company will retain rights to its respective product, and the collaboration is structured as non-exclusive.

Clinical trials are expected to begin dosing patients in mid-2026.